白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应

doi:10.35541/cjd.20190858

Abstract

Abstract: 【Abstract】 Interleukin （IL）-17A plays a key role in the occurrence and development of psoriasis. At present, several marketed IL-17A and its receptor antagonists have been applied to the treatment of psoriasis, and definite therapeutic effects have been achieved. However, several adverse reactions, including upper respiratory tract infection, Candida infections, neutropenia, inflammatory bowel disease, which can be life-threatening, have been reported in clinical trials and after marketing of these biologics. This review summarizes clinical safety profiles of 3 types of interleukin-17A and its receptor antagonists, i.e., secukinumab, ixekizumab and brodalumab.

Key words: Psoriasis, Biological agents, Interleukin-17, Receptors, interleukin-17, Antibodies, monoclonal, humanized, Drug toxicity, Infection, Candida albicans

Wang Ruojun, Li Ruoyu. Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2021, 54(2): 170-173.doi:10.35541/cjd.20190858

References ［23］

［1］	Gooderham M, Posso⁃De Los Rios CJ, Rubio⁃Gomez GA, et al. Interleukin⁃17 （IL⁃17） inhibitors in the treatment of plaque psoriasis: a review［J］. Skin Therapy Lett, 2015,20（1）:1⁃5.
［2］	Burkett PR, Kuchroo VK. IL⁃17 blockade in psoriasis［J］. Cell, 2016,167（7）:1669. doi: 10.1016/j.cell.2016.11.044.
［3］	李祥, 张小艳, 张理涛. 生物制剂治疗银屑病药物选择［J］. 中国中西医结合皮肤性病学杂志, 2019,18（1）:35⁃38. doi: 10. 3969/j.issn.1672⁃0709.2019.01.011.
［4］	Lockwood SJ, Prens LM, Kimball AB. Adverse reactions to biologics in psoriasis［J］. Curr Probl Dermatol, 2018,53:1⁃14. doi: 10.1159/000478072.
［5］	尹莉, 尹志强. 白介素⁃17家族与银屑病［J］. 中国麻风皮肤病杂志, 2017,33（1）:59⁃61.
［6］	Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials［J］. N Engl J Med, 2014,371（4）:326⁃338. doi: 10.1056/NEJMoa1314258.
［7］	van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long⁃term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:83⁃98.e4. doi: 10.1016/j.jaad.2016.03.024.
［8］	McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti⁃interleukin⁃17A monoclonal antibody, in patients with psoriatic arthritis （FUTURE 2）: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2015,386（9999）:1137⁃1146. doi: 10.1016/S0140⁃6736（15）61134⁃5.
［9］	Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med，2016，375（4）:345⁃356. doi:10.1056/NEJMoa1512711
［10］	Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis［J］. N Engl J Med, 2015,373（14）:1318⁃1328. doi: 10.1056/NEJMoa1503824.
［11］	Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate⁃to⁃severe plaque psoriasis: a systematic review and meta⁃analysis［J］. Clin Drug Investig, 2017,37（5）:439⁃451. doi: 10.1007/s40261⁃017⁃0500⁃9.
［12］	Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin⁃17 inhibitors and their practical management［J］. Br J Dermatol, 2017,177（1）:47⁃62. doi: 10.1111/bjd.15015.
［13］	Leonardi C, Matheson R, Zachariae C, et al. Anti⁃interleukin⁃17 monoclonal antibody ixekizumab in chronic plaque psoriasis［J］. N Engl J Med, 2012,366（13）:1190⁃1199. doi: 10.1056/NEJMoa 1109997.
［14］	Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double⁃blind, placebo⁃controlled study of brodalumab in patients with moderate⁃to⁃severe plaque psoriasis［J］. Br J Dermatol, 2016,175（2）:273⁃286. doi: 10.1111/bjd.14493.
［15］	Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment［J］. J Am Acad Dermatol, 2014,71（6）:1183⁃1190.e3. doi: 10.1016/j.jaad. 2014.08.039.
［16］	Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52⁃week, open⁃label study［J］. Br J Dermatol, 2017,176（3）:741⁃751. doi: 10.1111/bjd.14702.
［17］	Kamata M, Tada Y. Safety of biologics in psoriasis［J］. J Dermatol, 2018,45（3）:279⁃286. doi: 10.1111/1346⁃8138.14096.
［18］	Smith E, Stark MA, Zarbock A, et al. IL⁃17A inhibits the expansion of IL⁃17A⁃producing T cells in mice through "short⁃loop" inhibition via IL⁃17 receptor［J］. J Immunol, 2008,181（2）:1357⁃1364. doi: 10.4049/jimmunol.181.2.1357.
［19］	Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin⁃17 inhibition: role in psoriasis and inflammatory bowel disease［J］. J Dermatolog Treat, 2018,29（1）:13⁃18. doi: 10.1080/09546634. 2017.1329511.
［20］	王刚. 皮肤科生物制剂的主要不良反应及对策［J］. 中华皮肤科杂志, 2019,52（2）:77⁃80. doi: 10.3760/cma.j.issn.0412⁃4030. 2019.02.001.
［21］	Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti⁃interleukin⁃17⁃receptor antibody for psoriasis［J］. N Engl J Med, 2012,366（13）:1181⁃1189. doi: 10.1056/NEJMoa1109017.
［22］	AbuHilal M, Walsh S, Shear N. The role of IL⁃17 in the pathogenesis of psoriasis and update on IL⁃17 inhibitors for the treatment of plaque psoriasis［J］. J Cutan Med Surg, 2016,20（6）:509⁃516. doi: 10.1177/1203475416651605.
［23］	Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice［J］. Rheumatology （Oxford）, 2016,55（2）:210⁃220. doi: 10.1093/rheumatology/kev277.

[1]	Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275.
[2]	Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245.
[3]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263.
[4]	Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250.
[5]	Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218.
[6]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[7]	Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644.
[8]	Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631.
[9]	Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156.
[10]	Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184.
[11]	Zhao Ying, Wang Juanjuan, Ji Jiang, Su Wenxing, Wei Yuqian, Leng Hong, Ding Yujie, Shi Xin. Interleukin-17A-mediated psoriasis and cardiovascular comorbidities [J]. Chinese Journal of Dermatology, 2022, 55(1): 76-79.
[12]	Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75.
[13]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210420-e20210420.
[14]	Yang Lu, Duan Zhimin, Li Min. Mechanisms underlying the resistance of Candida albicans to echinocandin antifungals [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210273-e20210273.
[15]	Yang Rui, Kong Qingtao, Xu Jie, Zhang Chen, Sang Hong. Screening of susceptibility genes and an immunological study in a patient with recurrent cervical lymphadenitis caused by Candida albicans [J]. Chinese Journal of Dermatology, 2022, 55(1): 50-54.

Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［23］

Related Articles 15

Metrics

Comments

Recommended 10